Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma

Butterfield, Lisa H.; Vujanovic, Lazar; Santos, Patricia M.; Maurer, Deena M.; Gambotto, Andrea; Lohr, Joel; Li, Chunlei; Waldman, Jacob; Chandran, Uma; Lin, Yan; Lin, Huang; Tawbi, Hussein A.; Tarhini, Ahmad A.; Kirkwood, John M.

doi:10.1186/s40425-019-0552-x

Table 1 Patient Demographics and Outcomes

From: Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma

Patient Identifier	Gender	Age	Disease Site	Previous Therapy	Baseline Tumor Mutation^a	Trial Arm^b	Best Clinical outcome^c	Overall Survival^d	Progression Free Survival^d
1	F	82	Skin	Temodar 3 cycles (1.5 yrs. prior)	BRAF V 600 K	OBS	PD	6.3	3.2
2	M	74	Skin and chest wall	IL-2, IFNα, ipilimumab	BRAF V600E and NRAS	NR	PD	14.0	2.0
3	F	82	Skin	–	NRAS Q61R	NR	PD	13.6	2.1
4	M	74	Skin	–	None	NR	PD	1.0	0.8
5	M	44	Skin and brain	–	BRAF V600E	NR	PD	0.6	0.4
6	M	67	Nasal cavity	IFNα, vaccine + ipilimumab, IL-2	None	IFN	SD	39.8	5.5
7	M	42	Skin and lymph nodes	Ipilimumab, dacarbazine, IFNα, carboplatin + paclitaxel (2 mo. prior), pembrolizumab	None	OBS	SD	20.0	7.2
8	F	74	Skin	IFNα, DC vaccine, ipilimumab, pembrolizumab (11–090)	None	IFN	SD	13.0	8.7
9	M	66	Skin and lymph nodes	IFN, ipi, anti-PD-1	NRAS Q61K	IFN	SD	27.4	5.7
10	M	61	Skin and retroperitoneum	Ipilimumab	NRAS	OBS	PR	44.3	13.4
11	M	56	Skin and lymph nodes	IFNα, ipilimumab, IL-2, dacarbazine	None	NR	PD	14.8	1.7
12	M	44	Lymph nodes	–	NRAS	OBS	SD	41.7	3.9
13	M	74	Skin	IFNα	None	OBS	NED	42.5	18.4
14	F	58	Skin	IFNα	BRAF V600E	NR	PD	28.4	1.7
15	F	52	Skin	Ipilimumab	NRAS	IFN	NED	42.7	6.9
16	F	75	Vulva	IFNα	None	IFN	NED	38.6	9.3
17	M	64	Lymph nodes	IFNα, ipi, IL-2 + anti-VEGF	BRAF V600E	NR	PD	4.6	2.3
18	M	68	Skin	IFNα	None	OBS	NED	39.9	5.0
19	M	64	Skin	IFNα, DC vaccine	None	OBS	SD	3.5	3.2
20	M	60	Skin	–	None	IFN	PR	40.1	7.3
21	F	61	Skin	IFNα	None	OBS	NED	20.2	19.2
22	F	70	Lymph nodes	Ipi + IFNα	None	OBS	PD	3.0	2.0
23	M	28	Lung	IL-2 + anti-VEGF	None	NR	PD	11.2	2.1
24	F	42	Muscle	Ipi + Nivo, IL-2	None	OBS	PD	3.2	2.1
25	M	52	Skin and lymph nodes	–	BRAF V600K	NR	PD	0.6	0.6
26	M	60	Skin	IFNα	BRAF V600E	OBS	NED	36.1	3.6
27	F	59	Skin	–	n.t.	OBS	NED	35.8	13.7
28	M	47	Lymph nodes	IFNα, Nivo, Ipi	BRAF V600E	NR	PD	11.8	1.6
29	M	60	Skin	–	n.t.	IFN	NED	32.3	14.0
30	F	45	Skin	–	None	IFN	NED	37.5	37.5
31	M	66	Skin	IFNα	None	OBS	NED	37.3	30.7
32	F	41	Skin	IFNα	n.t.	OBS	NED	26.5	2.5
33	F	46	Lower limb and breast	IFNα, Ipi, IL-2, Pembro	BRAF V600E	NR	PD	1.6	0.9
34	M	88	Nasal cavity and lung	IFNα, Ipi, Pembro	None	OBS	SD	8.2	3.3
35	F	52	Skin and lymph node	GM-CSF (14 yrs. prior), IL-2, ipi	BRAF V600E	IFN	SD	24.2	13.0

^aTumor mutations identified in available baseline samples tested by clinical pathology sequencing test and/or by NanoString SNV panel, “n.t.” not tested, “None” tested and no mutation detected in panel
^bTrial arm: NR not randomized due to early progression, IFN randomized to IFN, OBS randomized to observation
^cPD progressive disease, SD stable disease, PR partial response, NED no evidence of disease (all by RECIST)
^dTime in months

Back to article page